Format

Send to

Choose Destination
Clin Lung Cancer. 2017 Nov;18(6):e473-e479. doi: 10.1016/j.cllc.2017.04.008. Epub 2017 Apr 24.

Programmed Death Ligand 1 Expression in Paired Non-Small Cell Lung Cancer Tumor Samples.

Author information

1
Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
2
Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
3
Department of Pathology & Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
4
Merck Research Laboratories, Merck & Co Inc, Kenilworth, NJ.
5
Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
6
Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.
7
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
8
Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark. Electronic address: henrikhager@mac.com.
9
Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: jkimsmc@skku.edu.

Abstract

BACKGROUND:

Programmed death ligand 1 (PD-L1) expression may predict response to anti-programmed death 1 (anti-PD-1) or anti-PD-L1 treatment. There is limited information on changes in PD-L1 expression over time in patients with non-small cell lung cancer (NSCLC).

PATIENTS AND METHODS:

Eligible patients with NSCLC who received surgery or underwent biopsy at Samsung Medical Center, Seoul, Republic of Korea, and Aarhus University Hospital, Aarhus, Denmark, between February 2004 and April 2012 were included. PD-L1 expression in paired tumor tissue samples from the same patients at different dates and lesions was measured using a laboratory-developed prototype immunohistochemistry assay (22C3 antibody). PD-L1 positivity was defined as tumor cell membrane positivity in ≥ 1% of tumor cells (proportion score). Concordance of PD-L1 expression was analyzed by treating proportion score as categoric or continuous variables.

RESULTS:

Ninety-one patients were included in the analysis. The median interval between the 2 tumor collection dates was 20 months, with 91% of paired samples collected > 3 months apart. The concordance rate for PD-L1 classification between paired samples was 67% (95% confidence interval, 57%-77%). When treating the immunohistochemistry proportional score as a continuous variable, a significant correlation of PD-L1 expression was observed between the paired samples (Pearson correlation coefficient, 0.61; P < .001).

CONCLUSION:

There are good correlations of PD-L1 expression from paired NSCLC samples. For patients whose PD-L1 status is negative, it may be valuable to obtain additional tissue samples for retesting PD-L1 expression when anti-PD-1 immunotherapy is considered.

KEYWORDS:

Immunomodulation; Laboratory correlates; NSCLC; PD-L1; Pembrolizumab

PMID:
28669849
DOI:
10.1016/j.cllc.2017.04.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center